ASX RELEASE 19 November 2026 Independent Phase 3 analysis supports new ROW trial for iPPS Key Highlights • Independent analysis confirms the previously reported ROW findings: TrialKey’s exploratory analysis showed statistically significant results favoring iPPS for Weekly Average Daily Pain...
Independent Review Supports New iPPS ROW Trial
Filed with ASX · · 6 pages · English
Release
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- September 2026 Quarterly Activities Report & Appendix 4C
- Convening Period Extended to 27 January 2027
- Deferral of AGM and Financial Reporting Obligations
- Extension of Convening Period
- Notification of cessation of securities - PAR
